Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvine Pharmaceuticals, Inc.

Latest From Alvine Pharmaceuticals, Inc.

Takeda Funds Celiac Asset As Prelude To Potential Acquisition

Takeda has started off the new year by continuing down the path of partnerships to strengthen its core therapeutic areas, this time linking up with a US academic spin-out for a potential oral therapy for celiac disease.

Research & Development Gastrointestinal

Celiac Research Partnership Builds Takeda’s GI Interests

Takeda continues to expand its interests in the gastrointestinal area through a joint research and development agreement with a small US venture for novel nanoparticle immune modulating therapies for celiac disease.

Gastrointestinal Cardiovascular

Financings Of The Fortnight And The Never-Ending Venture Round

While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.

BioPharmaceutical North America

Avalon/GSK Incubation Project Launches First Company, Focused On Celiac Disease

New company Sitari will try to develop first drug therapy for celiac disease. Portfolio companies launched by GSK and Avalon also will have their own, dedicated CRO-like organization to handle much of their work.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Nutraceuticals
  • Medical Devices
    • Diagnostic Equipment & Supplies